Published in Antimicrob Agents Chemother on July 01, 1998
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother (2004) 2.10
Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother (2004) 1.93
Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections. Proc Natl Acad Sci U S A (2014) 1.14
Pharmacodynamics of non-replicating viruses, bacteriocins and lysins. Proc Biol Sci (2006) 0.95
Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli. Antimicrob Agents Chemother (2005) 0.90
Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrob Agents Chemother (2003) 0.90
Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction. Biomed Res Int (2016) 0.88
Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. Antimicrob Agents Chemother (2015) 0.86
Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics. Theor Biol Med Model (2009) 0.77
Modeling the mechanism of postantibiotic effect and determining implications for dosing regimens. J Math Biol (2009) 0.76
Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis (1987) 5.63
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA (1981) 2.55
Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med (1984) 2.54
Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl (1990) 2.53
Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis Suppl (1990) 2.14
Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis (1990) 2.11
Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother (1996) 1.88
Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J Pharmacokinet Biopharm (1988) 1.32
The importance of pharmacodynamics in determining the dosing interval in therapy for experimental pseudomonas endocarditis in the rat. J Infect Dis (1986) 1.28
Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit (1993) 1.12
Pharmacodynamic factors of antibiotic efficacy. Pharmacotherapy (1992) 0.90
Prediction of future serum concentrations with Bayesian fitted pharmacokinetic models: results with data collected by nurses versus trained pharmacy residents. Ther Drug Monit (1994) 0.82
Adaptive control of therapeutic drug regimens relations between clinical situations: outcomes and simulations using nonlinear dynamic models. Medinfo (1995) 0.81
Letter: Creatinine clearance: bedside estimate. Ann Intern Med (1973) 2.52
An improved method of digoxin therapy. Ann Intern Med (1968) 2.19
Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother (1997) 2.13
Estimation of creatinine clearance when urine cannot be collected. Lancet (1971) 1.61
Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals. Clin Pharmacokinet (1998) 1.52
Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit (2001) 1.50
Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant (2003) 1.50
A nomogram for digoxin therapy. Am J Med (1974) 1.38
Reducation of digitalis toxicity by computer-assisted glycoside dosage regimens. Ann Intern Med (1972) 1.30
Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother (1999) 1.21
Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother (1990) 1.13
Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit (1993) 1.12
Clinical studies with computer-assisted initial lidocaine therapy. Arch Intern Med (1984) 1.11
Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis (2004) 1.11
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant (2001) 1.06
Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit (1994) 1.01
Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. Clin Pharmacol Ther (1991) 1.01
Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy (2001) 0.95
An improved method of digitoxin therapy. Ann Intern Med (1970) 0.94
Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant (2003) 0.92
Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy (1999) 0.92
Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. J Clin Pharm Ther (2006) 0.90
Serum cardiac glycoside assay based upon displacement of 3 H-ouabain from Na-K ATPase. Circulation (1972) 0.90
Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximisation (NPEM) algorithm. Clin Pharmacokinet (1992) 0.90
Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia. Pediatr Blood Cancer (2006) 0.88
Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study. Ther Drug Monit (2007) 0.88
Estimation of creatinine clearance from changing serum-creatinine levels. Lancet (1971) 0.88
Factors to consider in planning digoxin therapy. J Chronic Dis (1971) 0.87
The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. Proc Annu Symp Comput Appl Med Care (1991) 0.86
Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. J Clin Pharm Ther (2004) 0.86
Comparison of four methods for predicting serum gentamicin concentrations in surgical patients with perforated or gangrenous appendicitis. Clin Pharm (1987) 0.85
Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother (2000) 0.85
[Anaphylactic shock associated with ceftriaxone therapy in a newborn]. Arch Pediatr (2002) 0.83
Death from weight-control pills. A case report with objective postmortem confirmation. JAMA (1969) 0.83
Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant (2003) 0.83
[Case report of a patient treated with nicorandil who developed buccal aphthosis]. Therapie (1999) 0.82
Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother (2002) 0.82
Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. Eur J Clin Pharmacol (2001) 0.81
Adaptive control of therapeutic drug regimens relations between clinical situations: outcomes and simulations using nonlinear dynamic models. Medinfo (1995) 0.81
How many patients and blood levels are necessary for population pharmacokinetic analysis? A study of a one compartment model applied to cyclosporine. Eur J Clin Pharmacol (1996) 0.81
Cyclosporin A inhibits dendritic cell maturation promoted by TNF-alpha or LPS but not by double-stranded RNA or CD40L. J Leukoc Biol (2002) 0.81
Computer-controlled administration of cardiovascular drugs. Prog Cardiovasc Dis (1983) 0.81
Open-loop-feedback control of serum drug concentrations: pharmacokinetic approaches to drug therapy. Med Instrum (1983) 0.80
Editorial: Quantitative aspects of clinical judgment. Am J Med (1973) 0.79
Population pharmacokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage. J Clin Pharm Ther (2001) 0.79
Cytomegalovirus infection in pediatric allogenic hematopoietic stem cell transplantation. A single center experience. Pediatr Hematol Oncol (2013) 0.79
New sensitive assay of vancomycin in human plasma using high-performance liquid chromatography and electrochemical detection. J Chromatogr B Biomed Sci Appl (2001) 0.78
Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. Ther Drug Monit (1993) 0.78
[Aminoglycoside determinations calculated in endocarditis vegetations. Relations with clinical practices during infectious endocarditis treatment with amikacin]. Therapie (1994) 0.78
Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children. Eur J Clin Pharmacol (2001) 0.78
Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models. Biol Neonate (2001) 0.78
In vitro and in vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin. Acta Ophthalmol (Copenh) (1991) 0.78
Goal-oriented, model-based drug regimens. Comput Biol Med (2001) 0.77
A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. Ther Drug Monit (1998) 0.77
High-performance liquid chromatographic determination of ganciclovir in plasma. J Chromatogr (1991) 0.77
Administration of digoxin. Dis Chest (1969) 0.77
Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations. Comput Biol Med (2001) 0.77
Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Bone Marrow Transplant (2004) 0.77
Clinical use of ganciclovir during renal failure and continuous hemodialysis. Intensive Care Med (1994) 0.76
Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. Int J Biomed Comput (1994) 0.76
Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. J Clin Pharm Ther (2004) 0.76
Sodium hyaluronate as a carrier for intravitreal gentamicin. An experimental study. Acta Ophthalmol (Copenh) (1991) 0.75
Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. J Antimicrob Chemother (1998) 0.75
Antibiotic dose adjustment in renal insufficiency. Lancet (1992) 0.75
Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy. J Clin Pharm Ther (2010) 0.75
Human herpes virus-6 encephalitis in a paediatric bone marrow recipient: successful treatment with pharmacokinetic monitoring and high doses of ganciclovir. Bone Marrow Transplant (2006) 0.75
[A new tool for evaluation of medication errors applied to pediatric hematology]. Therapie (2002) 0.75
Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.75
Gentamicin and kanamycin nomograms. Ann Intern Med (1972) 0.75
Digitalis therapy: simple formulas to plan and adjust dosage regimens. MD Comput (1984) 0.75
Drug-receptor relationships, selection of therapeutic goals, and adaptive control of pharmacokinetic systems. Fed Proc (1987) 0.75
Automatic regulation for administration of therapeutic agents. IEEE Trans Biomed Eng (1987) 0.75
[Adaptive control of therapeutics using amikacin in very old patients: retrospective analysis of efficacy and toxicity]. Pathol Biol (Paris) (1994) 0.75
Electrolytes and cardiac arrhythmias. Crit Care Update (1980) 0.75
Efficacy and plasma levels of ropivacaine for children: controlled regional analgesia following lower limb surgery. Br J Anaesth (2006) 0.75
[Assessment of adherence to Afssaps guidelines for the prescription of antifungals in pediatric hemato-oncology]. Med Mal Infect (2010) 0.75
A fluorometric determination of myocardial digoxin at autopsy, with identification of digitalis leaf, digitoxin, and gitoxin. Am J Clin Pathol (1969) 0.75
[Vancomycin: what dosages are needed to achieve efficacy in paediatric hematology/oncology?]. Arch Pediatr (2011) 0.75
Kinetics of procainamide in anuric patients undergoing chronic hemodialysis. Proc Clin Dial Transplant Forum (1973) 0.75
An improved method for replacing one digitalis glycoside with another. Med Times (1970) 0.75
Autopsy verification of suicide by digitalis. Report of a case, with successful chemical identification of digitalis glycosides in gastric contents. Am J Clin Pathol (1967) 0.75
[Invasive fungal infections in oncology and haematology unit care: review of literature and costs analysis]. Ann Pharm Fr (2011) 0.75
[Human herpesvirus 6 encephalitis after bone marrow transplantation]. Arch Pediatr (2006) 0.75
N-Acetylprocainamide kinetics and clinical response during repeated dosing. Clin Pharmacol Ther (1982) 0.75
Computerized dosage regimens for highly toxic drugs. Am J Hosp Pharm (1974) 0.75
[Individual variability of pharmacokinetic parameters of amikacin in the elderly: retrospective studies]. Pathol Biol (Paris) (1996) 0.75
[Busulfan and cycosporin in bone graft children]. Ann Pharm Fr (2004) 0.75
The dental patient and the medical history. J Hosp Dent Pract (1967) 0.75
Common medical causes of headache. J Hosp Dent Pract (1969) 0.75
Preliminary results of three methods for population pharmacokinetic analysis (NONMEM, NPML, NPEM) of amikacin in geriatric and general medicine patients. Int J Biomed Comput (1994) 0.75
Planning drug doses for patients. Dent Dimens (1973) 0.75